Encouraging data on the safety and effectiveness of adefovir dipivoxil as a treatment for patients with lamivudine-resistant hepatitis B virus have been reported to the meeting of the European Association for the Study of the Liver (EASL).
The meeting in Prague, Czech Republic, received reports on four studies of the drug.
Dr Yves Benhamou, of the Groupe Hospitalier Pitie-Salpetriere, Paris, France, reported interim results of a study of 35 patients infected with HIV and HBV - with HBV resistance to lamivudine.
29 patients reached the 48th week of the study and showed significant reductions in mean levels of HBV, Dr Benhamou reported. There were no significant changes in renal function or serum electrolytes.
Adefovir dipivoxil significantly reduced HBV levels
|European Association for the Study of the Liver |
The pilot study is due to last for 96 weeks.
Dr Benhamou said, "The antiviral response observed in this study, tolerability and ease
of administration for adefovir dipivoxil suggest that the compound may be an important new treatment option for patients with lamivudine-resistant HBV and HIV infection.
"These results are important, given the high incidence of resistance to lamivudine in patients treated for HBV, and in particular patients co-infected with HIV and HBV."
Some 700 patients are taking part in international Phase III trials of the drug.
Dr Shelly Xiong, of developers Gilead Sciences, reported on a trial of 124 liver transplant patients infected with hepatitis B. The study suggests that different patterns of lamivudine resistance may not affect response rates to adefovir dipivoxil.
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com